Skip to main content
Whitehawk Therapeutics, Inc. logo

Whitehawk Therapeutics, Inc. — Investor Relations & Filings

Ticker · WHWK ISIN · US00032Q1040 LEI · 549300G3U7TKW1M58L09 US Professional, scientific and technical activities
Open in API
Filings indexed 516 across all filing types
Latest filing 2017-03-27 Major Shareholding Noti…
Country US United States of America
Listing US WHWK

About Whitehawk Therapeutics, Inc.

https://ir.whitehawktx.com/

Whitehawk Therapeutics, Inc. is a preclinical-stage oncology company focused on developing advanced antibody-drug conjugate (ADC) therapies. The company applies next-wave platform technologies to established tumor biology to create treatments for difficult-to-treat cancers. Its portfolio features three ADC assets, which are engineered to overcome the limitations of first-generation predecessors through improved tumor targeting and clinical strategies. These assets are in-licensed from WuXi Biologics under an exclusive agreement for global development and commercialization.

Recent filings

Filing Released Lang Actions
SC 13D Filing
Major Shareholding Notification
2017-03-27 English
3 Filing
Director's Dealing
2017-03-17 English
3 Filing
Director's Dealing
2017-03-17 English
3 Filing
Director's Dealing
2017-03-17 English
4 Filing
Director's Dealing
2017-03-17 English
8-K Filing
M&A Activity Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 15, 2017, by Aerpio Pharmaceuticals, Inc. It details a merger transaction, including the merger agreement, acquisition of assets, conversion of shares, and related corporate actions. The document includes detailed descriptions of the merger and related transactions, changes in corporate structure, and securities issued. It is not an annual or quarterly report, earnings release, or proxy statement. The primary focus is on the completion of an acquisition and related corporate events, which aligns with the category for merger-related announcements. Although it is a Form 8-K, the content specifically relates to merger and acquisition activity rather than general regulatory filings or other categories. Therefore, the appropriate classification is M&A Activity (Code: TAR).
2017-03-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.